Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study.
In this paper the authors review the completed and current EORTC Genitourinary Group trials for metastatic carcinoma of the prostate. In terms of time to progression and length of survival, there is no significant difference between any of the effective endocrine treatments that have been studied. The statistical analysis of the different variables used in trials 30,761 and 30,762 determines three risk groups of patients. There is no need for very special laboratory investigations to establish a prognosis. Orchiectomy is the cheapest and safest endocrine treatment in metastatic carcinoma of the prostate.
Bollack
C
C
Service du Chirurgie Urologique, Strasbourg, France.
Rougeron
G
G
D000726:Androgen Antagonists / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D005060:Europe; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D004961:Estramustine; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol; D017258:Medroxyprogesterone Acetate; D003534:Cyproterone; D008525:Medroxyprogesterone